Serological diagnosis of infectious mononucleosis using three anti-Epstein-Barr virus recombinant ELISAs by Färber, I. et al.
Journal of Virological Methods, 42 (1993) 301-308 
0 1993 Elsevier Science Publishers B.V. / All rights reserved / 0166-0934/93/$06.00 
301 
VIRMET 01481 
Serological diagnosis of infectious mononucleosis 
using three anti-Epstein-Barr virus 
recombinant ELISAs 
Inge Fgrber”, Peter Wutzlera, Peter Wohlrabe”, Hans Wolf”, 
Walter Hinderer” and Hans-Hermann Sonnebornc 
aInstitute of Medical Microbiology, Medical Academy, Erfurt (FRG), bInstitute of Medical 
Microbiology, University of Regensburg, Regensburg (FRG) and 
‘Research Department, Biotest AG, Dreieich (FRG) 
(Accepted 30 November 1992) 
Summary 
A new Epstein-Barr virus (EBV) ELISA system (Biotest Anti-EBV 
recombinant) was evaluated for usefulness for routine diagnosis of EBV 
primary infection. The assay system is composed of three different microtest 
plates coated with three highly purified recombinant EBV antigens. The early 
antigens ~138 (BALF2, truncated) and ~54 (BMRFl, whole sequence) are used 
as a mixture for testing IgM (assay 1) and IgG (assay 2) antibodies. In addition, 
the EBNA-1 antigen p72 (BKRFl, carboxy-half) is used for detecting IgG 
antibodies (assay 3). 
Three panels of sera were examined in direct comparison with standard 
immunofluorescence (IF): Specimens of (i) 120 infectious mononucleosis (IM) 
patients, (ii) 60 patients with acute CMV infection, toxoplasmosis or rheumatic 
disease, respectively, and (iii) 185 healthy blood donors as a control group. 
119 IM patients were clearly recognized as having acute primary infection 
(sensitivity 99.2% compared to VCA-IgM by IF). Three apparently false- 
positive results were obtained with patients of other diseases and none within 
the control group (specificity 98.8%). The data suggest that the recombinant 
ELISA can be used advantageously for standardized rapid diagnosis of acute 
EBV primary infection. 
Infectious mononucleosis; Serological diagnosis; Epstein-Barr virus; ELISA system 
Correspondence to; I. Flrber, Institute of Medical Microbiology, Medical Academy Nordhluser Str. 74, 
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Introduction 
Many years before the Epstein-Barr virus (EBV) was discovered serodiag- 
nosis of infectious mononucleosis (IM) was based on the Paul-Bunnell test for 
heterophile antibodies (Paul and Bunnell, 1932). Testing for heterophile 
antibodies is still widespread in routine diagnosis. However, despite the 
relatively high degree of specificity of the Paul-Bunnell agglutinins for the early 
stage of IM the test fails in some cases particularly with young children (Evans 
et al., 1975, Schmitz et al., 1972). Therefore, serodiagnosis of IM by measuring 
the specific antibody response is clearly to be preferred. 
Primary EBV infections whether or not accompanied by clinical signs of IM 
lead to the appearance of antibodies to various EBV-specific antigens which are 
usually detected by immunofluorescence (IF) staining of EBV infected cells 
(Henle et al., 1974). The typical antibody pattern of primary EBV infection is 
characterized by IgM and IgG antibodies to virus capsid antigen (VCA), IgG 
antibodies to early antigens (EA) and the absence of antibodies to nuclear 
antigens (EBNA). 
For routine purposes, immunofluorescence assays are time consuming. 
difficult to evaluate, and cannot be exactly standardized. Moreover, the 
evaluation of EBV-specific immunofluorescence may be considerably ham- 
pered by autoantibodies to various cellular antigens which emerge in the course 
of IM in most patients (Sutton et al., 1974). 
These problems might be solved by utilizing highly purified recombinant 
EBV polypeptides as antigens (Motz et al., 1986; Wolf et al., 1985). Several 
putative test-antigens have been evaluated extensively recently. (Hinderer et al., 
1988, Gorgievski-Hrisoho et al., 1990). Three were used to develop a new 
generation of EBV-ELISA (‘Biotest Anti-EBV recombinant’) for detecting IgG 
and IgM antibodies to EA (~138 and ~54) and IgG antibodies to EBNA (~72). 
The present study was designed to evaluate the usefulness of this new ELISA 
system for routine diagnosis of primary EBV infections. Well-defined cases of 
IM diagnosed by heterophile antibodies and EBV-specific standard immuno- 
fluorescence were investigated in comparison with two control groups, i.e. 
healthy blood donors and patients with other infectious or rheumatic diseases. 
Material and Methods 
Clinical specimens 
Sera were collected from 100 patients with heterophile positive IM (aged 4- 
29 yr, mean 12.9 yr) and 20 patients with heterophile negative IM (aged 2-12 
yr, mean 5,l yr). All cases were confirmed by positive VCA-IgM results 
( > 1: 10) using IF and a negative or weakly positive anti-EBNA result by means 
of anticomplement immunofluorescence (ACIF). Controls were 185 healthy 
blood donors. Another control group consisted of 60 patients with other 
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TABLE 1 
Recombinant EBV antigens 
Protein P54 
Reading frame BMRF 1 
Classification Early antigen (EA-D) 
Construction Whole coding region 
Size of expressed 52147 kDa 
protein (Mr) 
Concentration in 0.875 ,ng/ml 
coating solution 
~138 
BALF 2 
Early antigen (‘major 
DNA-binding protein’) 
Fusion of two 
selected sections 
39 kDa 
0.875 ,ug/ml 
~72 
BKRF 1 
Nuclear antigen 
(EBNA-I) 
C-terminal part (46.2%) 
46 kDa 
0.125 pg/ml 
infections (acute cytomegalovirus infection, n = 20; toxoplasmosis, II = 20) or 
rheumatic diseases (n = 20). 
Recombinant EB V antigens and ELISA procedure 
The assay system is composed of different microplate ELISAs for detecting 
IgM and IgG antibodies to highly purified recombinant EBV antigens 
immobilized onto the solid phase. The early antigens ~138 (BALF2, 
truncated) and p54 (BMRFl, whole sequence) are coated as a mixture for 
testing IgM and IgG antibodies. The EBNA-1 antigen p72 (BKRFl, carboxy- 
half) is used for detecting IgG antibodies. 
The construction of the clones and the concentrations in coating solutions 
are shown in Table 1. The configuration of the ELISA is given in Table 2. 
Sera were diluted 1:21 and incubated with the immobilized antigens 
(microtest plates, 96 wells) at 40°C for either 30 (IgG) or 60 (IgM) min. After 
washing steps the second antibody was incubated at 40°C for 30 min followed 
by further washing procedures. The reaction with substrate (1,2-phenylenedia- 
mine) was performed at room temperature for 15 min. All volumes were 100 ~1. 
The absorption values were measured at 492/620 nm. Blank, negative and 
positive controls were included on each plate. The cut-off values were defined 
as optical density (O.D.) of the negative control + 0.15. 
Standard laboratory diagnosis 
EBV-specific antibodies to VCA (IgG and IgM) and EA (IgG) were 
determined by indirect immunofluorescence (IF) on the basis of slides prepared 
from antigen producing P3HR-1 (VCA) and chemically induced Raji cells (EA 
R+ D) (Henle et al., 1974). To avoid nonspecific IgM reactivities due to the 
presence of rheumatoid factors and antigen-specific IgG the sera were 
preabsorbed by anti-IgG (RF-Absorbent, Behringwerke AG, FRG). 
Antibodies against EBNA were detected by ACIF on slides prepared from 
nonproducing Raji cells (Reedman and Klein, 1973). 
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Testing for heterophile antibodies was carried out by a modified Paul- 
Bunnell assay (Wiillner, 1962). Sera with a titer 3 1:12 were considered 
positive. 
Results 
The distribution of reactivities for each ELISA within the 3 panels of sera is 
shown in Table 2. Of the 120 IM sera tested all but one were positive by the 
IgM-ELISA, mostly (64.2%) with values of > 1 .OOO .D. By contrast, 96.2% 
of the healthy blood donors and 65.0% of the patients with cytomegalovirus 
infection, toxoplasmosis or rheumatic diseases were negative with this assay. 
The IgG ELISA yielded positive results with all samples from IM, half of 
which had very high absorption values (O.D. >2.000). The positive rate of 
blood donors was only 9.7%. However, 56.7% of patients with other diseases 
displayed EA-IgG reactivities. 
The EBNA-IgG ELISA showed a reverse situation. Among the IM sera 
92.5% were clearly negative for EBNA-IgG whereas 78.9% of the controls 
reacted with this antigen, mostly with high O.D. values (> 1.000). 
Concerning the results of three anti-EBV ELISA markers each patient was 
placed in a diagnostic scheme which covers the various stages of EBV infection 
(Table 3). The pattern indicative of primary infection (EA-IgM and -1gG 
positive; EBNA-IgG negative or at most weakly positive) were obtained with 
119 out of 120 IM cases. The remaining patient displayed an intermediate 
pattern between acute and past-infection. Therefore, the overall sensitivity of 
the ELISA system was 99.2%. 
None of the healthy blood donors had a pattern for primary infection. 
Within this group the specificity was 100%. In contrast, four samples had a 
pattern of primary infection within the panels of other diseases. Additional IF 
assays with these sera confirmed one of these four patients as primary EBV 
TABLE 2 
Distribution of reactivities of the three recombinant ELISAs 
Range of IgM-ELISA (~54 + ~138) IgG-ELISA (~54 + ~138) EBNA-ELISA (p72)- 
OD values -- 
IM Other Blood IM Other Blood IM Other Blood 
dis. (%) donors dis. (X) donors dis. (%) donors 
~- 
0 < cut-off 0.8 65.0 96.2 0 43.3 91.3 85.0 25.0 21.1 
cut-off-0500 18.3 20.0 1.6 10.0 33.3 2.2 15.0 10.0 7.6 
0.501-1.000 16.7 10.0 1.6 17.5 13.3 1.6 0 5.0 10.8 
1 .OOl-2.000 31.7 3.3 0.6 21.7 6.7 1.1 0 10.0 119 
> 2.000 32.5 1.7 0 50.8 3.3 1.8 0 50.0 48.6 
._ 
Comparison of acute IM sera (n = 120) with control groups of patients wtth other infectious or 
rheumatic diseases (n = 60) and healthy blood donors (n = 185). 
IM = infectious mononucleosis, other diseases: cytomegalovirus infections (n = 20), toxoplasmosis 
(n = 20), rheumatic diseases (n = 20). 
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infection, two as possible reactivations and one patient could not be diagnosed 
by reason of anti-cellular antibodies. The overall specificity was at least 98.8%. 
i.e. three out of 245 were apparently false-positives. A small portion of the 
healthy control group (6%) and a more significant portion of the disease 
control group (28%) exhibited a reactivity pattern indicative of EBV 
reactivation. 
Discussion 
EBV-specific tests for infectious mononucleosis are usually based on the 
presence of IgM antibodies to VCA and the absence of anti-EBNA antibodies. 
Anti-EA-IgG antibodies when detected by IF using induced EBV infected cells 
are present during acute IM in only two-thirds of the cases (Henle et al., 1971). 
However, when the antibody response to individual viral polypeptides was 
determined by immunoblot, IgG and IgM reactivity to the EA polypeptides 
~138 and ~45-52 was detectable in the first serum samples of all acutely infected 
IM patients (Middeldorp and Herbrink, 1988). Recently, Gorgievski-Hrisoho 
et al. (1990) tested several recombinant EBV antigens, selected by Wolf et al. 
(1985) and Motz et al. (1986), with respect to reactivity among well-defined IM 
sera. It was shown, that particularly the EA proteins ~138 and p54 were 
excellently recognized by sera from patients with acute IM. On this basis, and 
including the EBNA-1 protein p72 as the third marker, the novel recombinant 
ELISA was established. 
Our results from acute IM demonstrate the usefulness of these assays in 
routine diagnosis of acute primary EBV infection when compared with the 
standard IF technique as a gold standard. The marked differences in the 
reactivities with the three ELISAs between IM and control groups underline 
the high diagnostic potential of the assay system. Among the 100 cases of 
heterophile positive IM and the 20 cases of heterophile negative IM only one 
was not recognized as having acute primary EBV infection (sensitivity 99.2%). 
On the other hand, three apparently false-positive results were obtained with 
patients of other diseases and none within the control group of blood donors 
(specificity 98.8%). 
For the ELISAs a general pretreatment of serum specimens with rheumatoid 
factor (RF) absorbent was not incorporated since false-positive IgM results 
caused by RF are only to be expected in sera which are highly reactive for EA- 
IgG. However, high reactivity with the EA-IgG ELISA in combination with a 
negative or weakly positive EBNA-ELISA is a marker for acute primary EBV 
infection independently from the IgM reactivity. Pretreatment of serum 
specimen to absorb IgG should be performed when the marker constellation 
EBNA-IgG positive, EA-IgM weakly positive and EA-IgG strongly positive 
was obtained. 
In conclusion, the data indicate that the recombinant ELISA system yields 
not only results which are comparable with the standard IF methods but also 
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offers advantages, e.g. simple and rapid performance, objective reading of 
results, reduced interference with rheumatoid factor, however no interference 
with anti-cellular antibodies. 
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